Cargando…

Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation

SIMPLE SUMMARY: In this study, we investigated the role of vitamin D levels and the impact on immune response in patients with mCRC and propose a vitamin D cut-off level. Among several hematological, biochemical and immunological variables, we identified the neutrophils-to-lymphocytes ratio, CD4+ T...

Descripción completa

Detalles Bibliográficos
Autores principales: Morelli, Cristina, Rofei, Michela, Riondino, Silvia, Fraboni, Daniela, Torino, Francesco, Orlandi, Augusto, Tesauro, Manfredi, Del Vecchio Blanco, Giovanna, Federici, Massimo, Arkenau, Hendrik-Tobias, Formica, Vincenzo, Roselli, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179512/
https://www.ncbi.nlm.nih.gov/pubmed/35681576
http://dx.doi.org/10.3390/cancers14112594
_version_ 1784723294533976064
author Morelli, Cristina
Rofei, Michela
Riondino, Silvia
Fraboni, Daniela
Torino, Francesco
Orlandi, Augusto
Tesauro, Manfredi
Del Vecchio Blanco, Giovanna
Federici, Massimo
Arkenau, Hendrik-Tobias
Formica, Vincenzo
Roselli, Mario
author_facet Morelli, Cristina
Rofei, Michela
Riondino, Silvia
Fraboni, Daniela
Torino, Francesco
Orlandi, Augusto
Tesauro, Manfredi
Del Vecchio Blanco, Giovanna
Federici, Massimo
Arkenau, Hendrik-Tobias
Formica, Vincenzo
Roselli, Mario
author_sort Morelli, Cristina
collection PubMed
description SIMPLE SUMMARY: In this study, we investigated the role of vitamin D levels and the impact on immune response in patients with mCRC and propose a vitamin D cut-off level. Among several hematological, biochemical and immunological variables, we identified the neutrophils-to-lymphocytes ratio, CD4+ T lymphocytes and B lymphocytes as being closely related to vitamin D status with an impact on survival. ABSTRACT: Background: Vitamin D deficiency is a poor prognostic factor in metastatic colorectal cancer (mCRC); however, targeted supplementation trials have so far yielded limited results. We investigated clinical-laboratory parameters influencing vitamin D deficiency, with a particular focus on immune response, and the effect on survival. These parameters could help optimize targeted supplementation therapy. Methods: Association of plasma 25-hydroxyvitamin D (25(OH])D) with overall survival (OS) was assessed with the Hazard Ratio Smoothed Curve with Restricted Cubic Splines (HRSC-RCS) and maximally selected rank statistics (MSRS) in mCRC patients who underwent first-line chemotherapy. Several hematobiochemical variables were evaluated as predictors of vitamin D deficiency by means of Least Absolute Shrinkage and Selection Operator (LASSO) analysis. In a patient subset, peripheral lymphocyte subpopulations were also analyzed. Results: One hundred thirty-three mCRC patients were included. The median(m) baseline 25(OH)D was 10.8 ng/mL (range 3–53.4). HRSC-RCS revealed a linear association between 25(OH)D and OS. MSRS found 10 ng/mL as the optimal 25(OH)D cut-off. The median OS for 25(OH)D < 10 (n = 60) vs. > 10 ng/mL (n = 73) was 12.3 and 24.5 months, respectively (p = 0.002). The LASSO analysis identified high neutrophil-to-lymphocyte ratio (NLR > 3.5) as the strongest predictor of vitamin D deficiency (Odds Ratio 3.35, p 0.0009). Moreover, patients with low 25(OH)D levels (< 10 ng/mL) and high NLR (>3.5) had the shortest survival and patients with 25(OH)D >10 ng/mL and NLR <3.5 had the longest: mOS 8.1 and 28.1 months, respectively, HR 3.40 (1.76–6.59), p 0.0004. Besides the significant difference in NLR between 25(OH)D < and > 10 ng/mL patients (mNLR 3.6 vs. 2.9, p 0.03), the lymphocyte subpopulation analysis revealed that vitamin D deficiency was associated with high T- CD4+ (p = 0.04) and low B (p = 0.03) lymphocyte frequency. Conclusions: NLR is a powerful predictor of Vitamin D deficiency and can further help in stratifying prognosis. Vitamin D deficiency was associated with significant variations in peripheral immune cells. We hypothesize that integrated targeted interventions to both vitamin D and immune system would improve the prognosis of mCRC patients.
format Online
Article
Text
id pubmed-9179512
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91795122022-06-10 Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation Morelli, Cristina Rofei, Michela Riondino, Silvia Fraboni, Daniela Torino, Francesco Orlandi, Augusto Tesauro, Manfredi Del Vecchio Blanco, Giovanna Federici, Massimo Arkenau, Hendrik-Tobias Formica, Vincenzo Roselli, Mario Cancers (Basel) Article SIMPLE SUMMARY: In this study, we investigated the role of vitamin D levels and the impact on immune response in patients with mCRC and propose a vitamin D cut-off level. Among several hematological, biochemical and immunological variables, we identified the neutrophils-to-lymphocytes ratio, CD4+ T lymphocytes and B lymphocytes as being closely related to vitamin D status with an impact on survival. ABSTRACT: Background: Vitamin D deficiency is a poor prognostic factor in metastatic colorectal cancer (mCRC); however, targeted supplementation trials have so far yielded limited results. We investigated clinical-laboratory parameters influencing vitamin D deficiency, with a particular focus on immune response, and the effect on survival. These parameters could help optimize targeted supplementation therapy. Methods: Association of plasma 25-hydroxyvitamin D (25(OH])D) with overall survival (OS) was assessed with the Hazard Ratio Smoothed Curve with Restricted Cubic Splines (HRSC-RCS) and maximally selected rank statistics (MSRS) in mCRC patients who underwent first-line chemotherapy. Several hematobiochemical variables were evaluated as predictors of vitamin D deficiency by means of Least Absolute Shrinkage and Selection Operator (LASSO) analysis. In a patient subset, peripheral lymphocyte subpopulations were also analyzed. Results: One hundred thirty-three mCRC patients were included. The median(m) baseline 25(OH)D was 10.8 ng/mL (range 3–53.4). HRSC-RCS revealed a linear association between 25(OH)D and OS. MSRS found 10 ng/mL as the optimal 25(OH)D cut-off. The median OS for 25(OH)D < 10 (n = 60) vs. > 10 ng/mL (n = 73) was 12.3 and 24.5 months, respectively (p = 0.002). The LASSO analysis identified high neutrophil-to-lymphocyte ratio (NLR > 3.5) as the strongest predictor of vitamin D deficiency (Odds Ratio 3.35, p 0.0009). Moreover, patients with low 25(OH)D levels (< 10 ng/mL) and high NLR (>3.5) had the shortest survival and patients with 25(OH)D >10 ng/mL and NLR <3.5 had the longest: mOS 8.1 and 28.1 months, respectively, HR 3.40 (1.76–6.59), p 0.0004. Besides the significant difference in NLR between 25(OH)D < and > 10 ng/mL patients (mNLR 3.6 vs. 2.9, p 0.03), the lymphocyte subpopulation analysis revealed that vitamin D deficiency was associated with high T- CD4+ (p = 0.04) and low B (p = 0.03) lymphocyte frequency. Conclusions: NLR is a powerful predictor of Vitamin D deficiency and can further help in stratifying prognosis. Vitamin D deficiency was associated with significant variations in peripheral immune cells. We hypothesize that integrated targeted interventions to both vitamin D and immune system would improve the prognosis of mCRC patients. MDPI 2022-05-24 /pmc/articles/PMC9179512/ /pubmed/35681576 http://dx.doi.org/10.3390/cancers14112594 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Morelli, Cristina
Rofei, Michela
Riondino, Silvia
Fraboni, Daniela
Torino, Francesco
Orlandi, Augusto
Tesauro, Manfredi
Del Vecchio Blanco, Giovanna
Federici, Massimo
Arkenau, Hendrik-Tobias
Formica, Vincenzo
Roselli, Mario
Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
title Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
title_full Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
title_fullStr Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
title_full_unstemmed Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
title_short Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
title_sort immune response in vitamin d deficient metastatic colorectal cancer patients: a player that should be considered for targeted vitamin d supplementation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179512/
https://www.ncbi.nlm.nih.gov/pubmed/35681576
http://dx.doi.org/10.3390/cancers14112594
work_keys_str_mv AT morellicristina immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT rofeimichela immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT riondinosilvia immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT frabonidaniela immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT torinofrancesco immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT orlandiaugusto immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT tesauromanfredi immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT delvecchioblancogiovanna immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT federicimassimo immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT arkenauhendriktobias immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT formicavincenzo immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation
AT rosellimario immuneresponseinvitaminddeficientmetastaticcolorectalcancerpatientsaplayerthatshouldbeconsideredfortargetedvitamindsupplementation